Marksans Pharma gets USFDA nod for Cetirizine Hydrochloride Tablets

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) for over the counter (OTC) Cetirizine Hydrochloride Tablets 5 mg and 10mg. It is indicated for the treatment of the perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose. The product will be marketed under store brand labels and is comparable to the brand Zyrtec®.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 61.65 as compared to the previous close of Rs. 61.20. The total number of shares traded during the day was 311130 in over 2417 trades.

The stock hit an intraday high of Rs. 62.25 and intraday low of 60.50. The net turnover during the day was Rs. 19151658.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 USFDA ANDA Approval OTCProduct CetirizineHydrochloride